All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
On November 21, 2018, the United States Food & Drug Administration (FDA) granted accelerated approval to venetoclax in combination with azacitidine, decitabine or low-dose cytarabine (LDAC) for patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction therapy due to older age (≥ 75 years) or coexisting medical conditions. This decision was dependent upon the confirmatory phase III clinical trials, VIALE-A and VIALE-C.1
It has been announced that the VIALE-A trial (NCT02993523), comparing venetoclax plus azacitidine to placebo plus azacitidine, has met the dual primary endpoints, with the combination therapy leading to a significant improvement in overall survival (OS) and composite complete remission rate.2
In February 2020, it was announced that the phase III VIALE-C trial (NCT03069352), comparing venetoclax plus LDAC to placebo plus LDAC, failed to meet the primary endpoint of a significant improvement in OS in patients with newly diagnosed AML who are ineligible for intensive induction chemotherapy.
The full results from VIALE-A and VIALE-C are expected to be presented at an upcoming medical congress. The FDA has not yet commented about whether the results of the VIALE-A or VIALE-C trial will impact the current approval.1
The AML Hub are currently focusing on an editorial theme of ‘novel combination therapies using targeted agents’. Venetoclax is a targeted agent that inhibits Bcl-2 and is under investigation in various combination therapies, such as with the hypomethylating agents azacitidine and decitabine, as discussed here. To learn more about targeted agent combinations in AML, click here.
FDA approves venetoclax in combination for AML in adults. https://www.fda.gov/drugs/fda-approves-venetoclax-combination-aml-adults. Updated Dec 14, 2018. [Accessed Mar 24, 2020]
Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia. https://www.roche.com/media/releases/med-cor-2020-03-23.htm. Published Mar 23, 2020. [Accessed Mar 24, 2020]
Clinicaltrials.gov. A study of venetoclax in combination with azacitidine versus azacitidine in treatment naïve subjects with acute myeloid leukemia who are ineligible for standard induction therapy. https://clinicaltrials.gov/ct2/show/NCT02993523. Updated Feb 28, 2020. [Accessed Mar 24, 2020]
PR Newswire. AbbVie provides update from phase 3 study evaluating VENCLEXTA® (venetoclax) in combination with low-dose cytarabine in newly-diagnosed patients with acute myeloid leukemia (AML). https://www.prnewswire.com/news-releases/abbvie-provides-update-from-phase-3-study-evaluating-venclexta-venetoclax-in-combination-with-low-dose-cytarabine-in-newly-diagnosed-patients-with-acute-myeloid-leukemia-aml-301013711.html. Published Feb 28, 2020. [Accessed Mar 24, 2020]
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox